Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial
Published in
The Lancet Diabetes & Endocrinology, September 2013
This research output has an Altmetric Attention Score of 94. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 July 2026.
All research outputs
#576,808
of 34,631,266 outputs
Outputs from The Lancet Diabetes & Endocrinology
#493
of 2,641 outputs
Outputs of similar age
#3,828
of 248,960 outputs
Outputs of similar age from The Lancet Diabetes & Endocrinology
#4
of 44 outputs
Altmetric has tracked 34,631,266 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,641 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 83.5. This one has done well, scoring higher than 81% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 248,960 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 44 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 90% of its contemporaries.
